Drug-induced liver injury in humans: The case of ximelagatran

Handbook of Experimental Pharmacology

Volumn 196, Issue , 2010, Pages 407-418

  Andersson, T B ^a,b   Keisu, M ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NONE

Author keywords

Bilirubin; In vitro liver toxicity models; Pharmacogenetics; Thrombin inhibitor; Transaminases; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; BILIRUBIN; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; GENOTYPE; HEART FIBRILLATION; HUMAN; JAUNDICE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LUNG EMBOLISM; MORTALITY; NAUSEA; NONHUMAN; PATIENT MONITORING; PHARMACOGENETICS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TOXIC HEPATITIS; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; DRUG RECALL; DRUG SCREENING; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; IMMUNOLOGY; LIVER; RISK ASSESSMENT; RISK FACTOR; TOXICITY TESTING;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; PHARMACOGENETICS; RISK ASSESSMENT; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; SEVERITY OF ILLNESS INDEX; TOXICITY TESTS;

EID: 77949312944     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00663-0_13     Document Type: Review

References (33)

1. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B (2009) On behalf of the EXTEND Study Group. Submitted for publication
2. Ansell J, Hirsch J, Dahlen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D (2001) Managing oral anticoagulant therapy. Chest 119(Suppl 1):22S-38S
3. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J (1997) HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 156:1601-1605
4. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777
5. Clement B, Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Met Disp 31:645-651
6. De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11:203-209
7. Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R (1998) Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 98:13-23
8. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ögren M (2003a) Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 89:288-296
9. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M (2003b) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Thromb Haemost 1:2490-2496
10. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D (2003c) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Met Disp 31:294-305
11. Executive Steering committee on behalf of the SPORIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared withwarfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698
12. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Clifford W, Colwell CW Jr (2002) Ximelagatran versus Warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind trial. Ann Intern Med 137:648-655
13. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Guy Paiement G, Peters GR (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349:1703-1712
14. Gibert M, Sanchez-Mazas A (2003) Geographic patterns of functional categories of HLA-DRB1 alleles: a new approach to analyse associations between HLA-DRB1 and disease. Eur J Immunogenet 30:361-374
15. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312
16. Hirsch J, Dahlen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(Suppl):8S-21S
17. Kenne K, Skanberg I, Glinghammar B, Berson B, Pessayre D, Flinois J-P, Beaune P, Edebert I, Diaz Pohl C, Carlsson T, Andersson TB (2008) Prediction of drug induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730-746
18. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström- Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel THE, Billing-Clason SM, Cardon LR, March RE (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom J 8:186-195
19. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485
20. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351-370
21. Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M (2008) Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of ximelagatran. Int J Clin Pharmacol Ther 46: 327-329
22. Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. New Eng J Med 354:731-739
23. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Ann Rev Pharmacol Toxicol 45:177-202
24. Petersen P, Grind M, Adler J et al (2003) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose guiding tolerability and safety study. J Am Coll Cardiol 41:1445-1451
25. Pichler WJ (2002) Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2:301-305
26. Repa JJ, Mangelsdorf DJ (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann Rev Cell Dev Biol 16:459-481
27. Schulman S, Wåhlander K, Lundström T, Billing Clason S, Eriksson H for the THRIVE III Investigators (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin tnhibitor ximelagatran. N Engl J Med 349:1713-1721
28. SPORTIF Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs Warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA 293:690-698
29. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodwin A, Nyström P, Bylock A (2003) Oral ximelagatarn for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789-797
30. Wang H, LeCluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokin 42:1331-1357
31. Wolzt M, Wollbratt M, Svensson M, Wåhlander K, Grind M, Eriksson UG (2003) Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 59:537-543 (Pubitemid 37363566)
32. Wolzt M, Sarich TS, Eriksson UG (2005) Pharmacokinetics and pharmacodynamics of ximelagatran. Sem Vasc Med 5:245-253
33. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293:681-689